#	Pagina
attuale pagina	/open-h2020/projects/226450/index.html
-1	/open-h2020/projects/228047/index.html
-2	/open-h2020/projects/222905/index.html

Opendata, web and dolomites

HAP2 SIGNED

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Total Cost €

EC-Contrib. €

Partnership

Views

HAP2 project word cloud

Explore the words cloud of the HAP2 project. It provides you a very rough idea of what is the project "HAP2" about.

genetic acquired ifn drugs interdisciplinary incidence capitalising disease cure il complete episodes first frequent pneumonia treatment industry predict course consumption reappraisal revolutionize despite omics antibiotic illness critical 500 axis pathogens hospitals immunosuppression clinical therapies recommendations medicine defective risk interactions sciences social urgently trials fight resistance supplementation immunology microbiome academia 30 hospital physiopathology uniquely alternative altering respiratory ambition infectious drug ground world survival stratified placed resistant biomarkers clinico variation hap2 strategies pathogen biological 12 score directed gamma severe dramatic infection infections outcome integrative expertise diseases dysbiosis breaking preventive precision hap prevention medical host patients bacterial

Project "HAP2" data sheet

The following table provides information about the project.

Coordinator	CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES Organization address address: Allee de l'Ile Gloriette 5 city: NANTES postcode: 44093 website: www.chu-nantes.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Total cost	9˙996˙350 €
EC max contribution	9˙996˙350 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2019-Two-Stage-RTD
Funding Scheme	RIA
Starting year	2020
Duration (year-month-day)	from 2020-01-01 to 2024-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES Organization address address: Allee de l'Ile Gloriette 5 city: NANTES postcode: 44093 website: www.chu-nantes.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (NANTES)	coordinator	3˙642˙770.00
2	UNIVERSITAT ZURICH UNIVERSITAT ZURICH Organization address address: RAMISTRASSE 71 city: ZURICH postcode: 8006 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (ZURICH)	participant	1˙510˙587.00
3	UNIVERSITE DE NANTES UNIVERSITE DE NANTES Organization address address: QUAI DE TOURVILLE 1 city: NANTES CEDEX 1 postcode: 44035 website: www.univ-nantes.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (NANTES CEDEX 1)	participant	1˙273˙025.00
4	FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA Organization address address: CARRER ROSSELLO 149 city: BARCELONA postcode: 8036 website: www.fundacioclinic.org contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BARCELONA)	participant	841˙365.00
5	STICHTING KATHOLIEKE UNIVERSITEIT STICHTING KATHOLIEKE UNIVERSITEIT Organization address address: GEERT GROOTEPLEIN NOORD 9 city: NIJMEGEN postcode: 6525 EZ website: www.radboudumc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (NIJMEGEN)	participant	785˙000.00
6	NEUMEDICINES INC. NEUMEDICINES INC. Organization address address: 10426 HELENDALE AVE city: TUJUNGA CA postcode: 91042 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	US (TUJUNGA CA)	participant	732˙127.00
7	BIG DATA SANTE BIG DATA SANTE Organization address address: RUE CONDORCET city: NANTES postcode: 44100 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (NANTES)	participant	477˙328.00
8	UNIVERSITY OF MICHIGAN THE REGENTS OF THE UNIVERSITY OF MICHIGAN UNIVERSITY OF MICHIGAN THE REGENTS OF THE UNIVERSITY OF MICHIGAN Organization address address: SOUTH STREET 3003 1068 city: ANN ARBOR postcode: 46109 1274 website: http://www.umich.edu contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	US (ANN ARBOR)	participant	322˙837.00
9	HOSPICES CIVILS DE LYON HOSPICES CIVILS DE LYON Organization address address: QUAI DES CELESTINS 3 city: LYON postcode: 69002 website: www.chu-lyon.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (LYON)	participant	315˙227.00
10	ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON Organization address address: 6 CHRISTOU LADA STR city: ATHINA postcode: 10561 website: www.elke.uoa.gr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	EL (ATHINA)	participant	96˙081.00

Map

Project objective

“HAP2” aims to develop stratified host-directed drugs and biomarkers to enhance the prevention and the treatment of hospital-acquired pneumonia (HAP) and develop precision medicine in infectious diseases. HAP is an infectious disease of major concern in the world, and the most frequent cause of hospital-acquired infections with 500,000 episodes being treated every year in Europe. Despite the development of European recommendations, the incidence remains high, with dramatic medical consequences: existing therapies and preventive measures do not result in the expected favourable outcome (clinical cure and survival) for 30% of patients. HAP are moreover the main cause of antibiotic consumption in European hospitals and are increasingly induced by drug-resistant pathogens. New, alternative and more effective host-targeted strategies are therefore urgently needed to fight antibiotic resistance. The ambition of “HAP2” is to revolutionize the management of HAP: capitalising on the novel concept of critical-illness related immunosuppression altering the host-pathogens interactions, we propose a complete reappraisal of the physiopathology of HAP based on the concept of respiratory dysbiosis. “The HAP2” project will reach two ground-breaking objectives in the field of bacterial infections: first the development of host-targeted approaches for the prevention and the treatment of a severe bacterial infection through the supplementation of the IL-12/IFN-γ axis which is defective in patients at risk of pneumonia; second the development of a clinico-biological score based on an integrative assessment of the host-pathogen interactions and genetic variation, to predict the course of HAP and the response to treatment. Our interdisciplinary consortium, bringing together 10 partners from academia and industry with expertise in clinical trials, immunology, microbiome analysis, omics and social sciences is uniquely placed to achieve this ambition within this 5-year project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HAP2" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HAP2" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination